News | April 05, 2021
Piramal Enterprises forays into peptide with Hemmo Pharma : ICICI Securities
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
New facility will open by October 2026 and house 500 process development specialists
Approval is based on results from the phase 3 OASIS 4 clinical trial
Accomplished molecular microbiologist and protein engineer takes charge of CSIR-IMTECH after serving in key scientific and regulatory leadership roles at FSSAI
The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format
Targeting deadly drug-resistant acinetobacter infections
The move signals a major expansion in access to next-generation weight-loss therapies
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
